论文部分内容阅读
目的探讨参麦注射液辅助支气管动脉介入治疗中晚期肺癌的临床疗效及安全性。方法将82例中晚期肺癌患者分为观察组(53例)和对照组(29例),对照组予支气管动脉介入治疗,观察组在此基础上加用参麦注射液辅助治疗,观察两组患者治疗疗效及毒副反应情况。结果观察组治疗有效率71.69%,明显高于对照组的55.17%(P<0.05);观察组出现恶心呕吐及白细胞减少病例明显低于对照组(P<0.05),1年生存率、2年生存率均明显高于对照组(P<0.05)。结论在支气管动脉介入治疗基础上加用参麦注射液辅助治疗中晚期肺癌,可有效提高疗效,减少毒副反应。
Objective To investigate the clinical efficacy and safety of Shenmai injection-assisted bronchial artery interventional therapy for advanced lung cancer. Methods 82 patients with advanced lung cancer were divided into observation group (n = 53) and control group (n = 29). The control group was treated with bronchial artery intervention. On the basis of this study, the observation group was treated with Shenmai injection. Patient treatment efficacy and side effects. Results The effective rate of observation group was 71.69%, which was significantly higher than that of control group (55.17%, P <0.05). The incidence of nausea and vomiting and leukopenia in observation group was significantly lower than that of control group (P <0.05), 1 year survival rate, 2 years Survival rate was significantly higher than the control group (P <0.05). Conclusion In addition to the interventional treatment of bronchial artery with Shenmai injection in the treatment of advanced lung cancer, which can effectively improve the curative effect and reduce the side effects.